eLetters

6 e-Letters

published between 2003 and 2006

  • Response to commentary
    Seena Fazel

    Dear Editor,

    Peters discusses some limitations in relation to our systematic review of the prevelance of substance abuse and dependence in prisoners. Peters states that we have not disaggregated findings obtained from sentenced and unsentenced prisoners. In fact, in Table 3, we do present the findings of sentenced and remand prisoners separately by gender, and by type of substance (alcohol and drug).

    Pet...

    Show More
  • Statement link missing
    Thorsten Schumann

    Dear Editor,

    It would have been utterly helpful if you had included a citation for the APA-NAMI-NMHA-statement in your article - or the following hypertext- link: http://www.nmha.org/newsroom/system/news.vw.cfm?do=vw&rid=662.

    Kind regards,

    Th. Schumann

  • Protection at home or risks away
    Andrew Al-Adwani

    Dear Editor,

    Is it not just as plausible to postulate a relative protection from schizophrenia in less developed countries that is inversely proportional to their degree of development. In this scenario the schizophrenia genotypes would be more prevalent in these countries and only become more liable to expression upon migration. This of course would be particularly so for those in the high risk years which a numbe...

    Show More
  • Risperidone improves tardive dyskinesia- are the benefits maintained in the longer term?
    C Feroz-Nainar

    Dear Editor,

    It would be interesting to know what proportion of the sample that had the initial positive response maintain the improvement in the longer term. This is important as tardive dyskinesia characteristically occurs after prolonged neuroleptic therapy. There are several case reports of long-term risperidone therapy causing tardive dyskinesia [1-5]. Recently a child in my clinic developed tardive dyskines...

    Show More
  • Buprenorphine is not a "symptomatic" treatment
    Andrew Al-Adwani

    Dear Editor

    The title and content of this article give the impression that buprenorphine is akin to symptomatic treatments like clonidine, lofexidine and the various cocktails of drugs added to these drugs during detoxification.

    We have been using buprenorphine detoxification for over a year with good results. However, it should be recognized that buprenorphine is a drug of abuse and more like methadone or...

    Show More
  • Whether social phobia or social anxiety disorder,other studied show different results?
    A.K Al-Sheikhli

    Dear Editor

    It was interesting to read the paper of Haug et al.[1] I have a number of comments:

    1.The SSRI group of anti-depressant medications are the best-established drug treatment for social anxiety disorder.[2] However, Veale in his review article shows that CBT is the initial of choice of treatment for social phobia.[3]

    2.I think the authors should have included other treatment o...

    Show More